Open access · CC-BY
via OpenAlex
Nanoengineered mesenchymal stem cell therapy for pulmonary fibrosis in young and aged mice
Meng‐Meng Han, Xing-Yue He, Tang Ling, Qi Liang, Ming‐Yuan Yang, Yi Wang, Lei Xing, Jee‐Heon Jeong, Hu‐Lin Jiang
Science Advances · 2023 · ▲ 84 citations
Abstract
Pulmonary fibrosis (PF) is an age-related interstitial lung disease that results in notable morbidity and mortality. The Food and Drug Administration-approved drugs can decelerate the progression of PF; however, curing aged patients with severe fibrosis is ineffective because of insufficient accumulation of these drugs and wide necrocytosis of type II alveolar epithelial cells (AEC IIs). Here, we constructed a mesenchymal stem cell (MSC)-based nanoengineered platform via the bioconjugation of MSCs and type I collagenase-modified liposomes loaded with nintedanib (MSCs-Lip@NCAF) for treating severe fibrosis. Specifically, MSCs-Lip@NCAF migrated to fibrotic lungs because of the homing characteristic of MSCs and then Lip@NCAF was sensitively released. Subsequently, Lip@NCAF ablated collagen fibers, delivered nintedanib into fibroblasts, and inhibited fibroblast overactivation. MSCs differentiated into AEC IIs to repair alveolar structure and ultimately promote the regeneration of damaged lungs in aged mice. Our findings indicated that MSCs-Lip@NCAF could be used as a promising therapeutic candidate for PF therapy, especially in aged patients.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1126/sciadv.adg5358
- Canonical
- link ↗
- Fetched
- 2026-09-21 MST
Cite this
APA
Han, M., He, X., Ling, T., Liang, Q., Yang, M., Wang, Y., Xing, L., Jeong, J., & Jiang, H. (2023). Nanoengineered mesenchymal stem cell therapy for pulmonary fibrosis in young and aged mice. <em>Science Advances</em>. https://doi.org/10.1126/sciadv.adg5358
Vancouver
Han M, He X, Ling T, Liang Q, Yang M, Wang Y, et al. Nanoengineered mesenchymal stem cell therapy for pulmonary fibrosis in young and aged mice. Science Advances. 2023. doi:10.1126/sciadv.adg5358.
BibTeX
@article{mengmeng2023Nanoen,
title = {Nanoengineered mesenchymal stem cell therapy for pulmonary fibrosis in young and aged mice},
author = {Meng‐Meng Han and Xing-Yue He and Tang Ling and Qi Liang and Ming‐Yuan Yang and Yi Wang and Lei Xing and Jee‐Heon Jeong and Hu‐Lin Jiang},
journal = {Science Advances},
year = {2023},
doi = {10.1126/sciadv.adg5358},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Biomolecules & therapeutics 2026
Open access · OA
Cellular Senescence: Emerging Therapeutic Target for Idiopathic Pulmonary Fibrosis Pathogenic Mechanisms and Therapeutic Strategies.
European Respiratory Journal 2017
Open access · CC-BY
Senolytic drugs target alveolar epithelial cell function and attenuate experimental lung fibrosis ex vivo
Current Tissue Microenvironment Reports 2022
Preprint · OA
The Vasculature in Pulmonary Fibrosis
Journal of Internal Medicine 2007
Open access · OA
Immunomodulation by mesenchymal stem cells and clinical experience
World Journal of Stem Cells 2021
Open access · CC-BY
Targeting mesenchymal stem cell therapy for severe pneumonia patients
Frontiers in Pharmacology 2022
Open access · CC-BY